An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
10.1038/35097089
Crossref journal-article
Springer Science and Business Media LLC
Nature (297)
Bibliography

Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413(6855), 527–531.

Authors 7
  1. David Panikashvili (first)
  2. Constantina Simeonidou (additional)
  3. Shimon Ben-Shabat (additional)
  4. Lumír Hanuš (additional)
  5. Aviva Breuer (additional)
  6. Raphael Mechoulam (additional)
  7. Esther Shohami (additional)
References 31 Referenced 599
  1. Povlishock, J. T. & Christman, C. W. The pathobiology of traumatically induced axonal injury in animals and humans: A review of current thoughts. J. Neurotrauma 12, 555–564 (1995). (10.1089/neu.1995.12.555) / J. Neurotrauma by JT Povlishock (1995)
  2. Kochanek, P. M. et al. Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. Pediatr. Crit. Care Med. 1, 4–19 (2000). (10.1097/00130478-200007000-00003) / Pediatr. Crit. Care Med. by PM Kochanek (2000)
  3. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995). (10.1016/0006-2952(95)00109-D) / Biochem. Pharmacol. by R Mechoulam (1995)
  4. Sugiura, T. et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97 (1995). (10.1006/bbrc.1995.2437) / Biochem. Biophys. Res. Commun. by T Sugiura (1995)
  5. Mechoulam, R., Fride, E. & Di Marzo, V. Endocannabinoids. Eur. J. Pharmacol. 359, 1–18 (1998). (10.1016/S0014-2999(98)00649-9) / Eur. J. Pharmacol. by R Mechoulam (1998)
  6. Piomelli, D., Giuffrida, A., Calignano, A. & Rodriguez de Fonseca, F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21, 218–223 (2000). (10.1016/S0165-6147(00)01482-6) / Trends Pharmacol. Sci. by D Piomelli (2000)
  7. Axelrod, J. & Felder, C. C. Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem. Res. 23, 575–581 (1998). (10.1023/A:1022418217479) / Neurochem. Res. by J Axelrod (1998)
  8. McIntosh, T. K., Juhler, M. & Wieloch, T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury J. Neurotrauma 15, 731–769 (1998). (10.1089/neu.1998.15.731) / J. Neurotrauma by TK McIntosh (1998)
  9. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5–R7 (2000). (10.1016/S0014-2999(00)00653-1) / Eur. J. Pharmacol. by R Gallily (2000)
  10. Chan, P. H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21, 2–14 (2001). (10.1097/00004647-200101000-00002) / J. Cereb. Blood Flow Metab. by PH Chan (2001)
  11. Shohami, E., Ginis, I. & Hallenbeck, J. M. Dual role of tumor necrosis factor α in brain injury. Cytokines Growth Factor Rev. 10, 119–130 (1999). (10.1016/S1359-6101(99)00008-8) / Cytokines Growth Factor Rev. by E Shohami (1999)
  12. Chen, Y., Constantini, S., Trembovler, V., Weinstock, M. & Shohami, E. An experimental model of closed head injury in mice: Pathophysiology, histopathology and cognitive deficits. J. Neurotrauma 13, 557–568 (1996). (10.1089/neu.1996.13.557) / J. Neurotrauma by Y Chen (1996)
  13. Beni-Adani, L. et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J. Pharmacol. Exp. Ther. 296, 57–63 (2001). / J. Pharmacol. Exp. Ther. by L Beni-Adani (2001)
  14. Mathews, K. S. et al. Rapid quantification of ischaemic injury and cerebroprotection in brain slices using densitometric assessment of 2,3,5-triphenyltetrazolium chloride staining. J. Neurosci. Meth. 102, 43–51 (2000). (10.1016/S0165-0270(00)00277-6) / J. Neurosci. Meth. by KS Mathews (2000)
  15. Ben-Shabat, S. et al. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23–31 (1998). (10.1016/S0014-2999(98)00392-6) / Eur. J. Pharmacol. by S Ben-Shabat (1998)
  16. Adams, I. E., Compton, D. R. & Martin, B. R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284, 1209–1217 (1998). / J. Pharmacol. Exp. Ther. by IE Adams (1998)
  17. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293, 136–150 (2000). / J. Pharmacol. Exp. Ther. by SR Smith (2000)
  18. Shohami, E., Shapira, Y., Yadid, G., Reisfeld, N. & Yedgar, S. Brain phospholipase A2 is activated after experimental closed head injury in rats. J. Neurochem. 53, 1541–1546 (1989). (10.1111/j.1471-4159.1989.tb08550.x) / J. Neurochem. by E Shohami (1989)
  19. Nadler, V., Biegon, A., Beit-Yannai, E., Adamchik, J. & Shohami, E. 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res. 685, 1–11 (1995). (10.1016/0006-8993(95)00367-Y) / Brain Res. by V Nadler (1995)
  20. Reggio, P. H. & Traore, H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids 108, 15–35 (2000). (10.1016/S0009-3084(00)00185-7) / Chem. Phys. Lipids by PH Reggio (2000)
  21. Goparaju, S. K., Ueda, N., Yamaguchi, H. & Yamamoto, S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422, 69–73 (1998). (10.1016/S0014-5793(97)01603-7) / FEBS Lett. by SK Goparaju (1998)
  22. Sinor, A. D., Irvin, S. M. & Greenberg, D. A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157–160 (2000). (10.1016/S0304-3940(99)00922-2) / Neurosci. Lett. by AD Sinor (2000)
  23. Shen, M. & Thayer, S. A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459–462 (1998). (10.1124/mol.54.3.459) / Mol. Pharmacol. by M Shen (1998)
  24. Nagayama, T. et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987–2995 (1999). (10.1523/JNEUROSCI.19-08-02987.1999) / J. Neurosci. by T Nagayama (1999)
  25. van der Stelt, M. et al. Neuroprotectin by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21, 6475–6479 (2001). (10.1523/JNEUROSCI.21-17-06475.2001) / J. Neurosci. by M van der Stelt (2001)
  26. Hansen, H. S., Moesgaard, B., Hansen, H. H. & Petersen, G. N-acylethanolamines and percursor phospholipids—relation to cell injury. Chem. Phys. Lipids 108, 135–150 (2000). (10.1016/S0009-3084(00)00192-4) / Chem. Phys. Lipids by HS Hansen (2000)
  27. Shohami, E. & Mechoulam, R. Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. Drug Develop. Res. 50, 211–215 (2000). (10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G) / Drug Develop. Res. by E Shohami (2000)
  28. Sugiura, T., Yoshinaga, N., Kondo, S., Waku, K. & Ishima, Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem. Biophys. Res. Comm. 271, 654–658 (2000). (10.1006/bbrc.2000.2686) / Biochem. Biophys. Res. Comm. by T Sugiura (2000)
  29. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225, 1–8 (2000). (10.1046/j.1525-1373.2000.22501.x) / Proc. Soc. Exp. Biol. Med. by TW Klein (2000)
  30. Ovadia, H., Wohlman, A., Mechoulam, R. & Weidenfeld, J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 34, 175–180 (1995). (10.1016/0028-3908(94)00133-D) / Neuropharmacology by H Ovadia (1995)
  31. Chen, Y. et al. Human brain capillary endothelium. 2-Arachidonoylglycerol (endocannabinoid) interacts with endothelin-1. Circ. Res. 87, 323–327 (2000). (10.1161/01.RES.87.4.323) / Circ. Res. by Y Chen (2000)
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 4:32 a.m.)
Deposited 2 years, 3 months ago (May 16, 2023, 10:11 p.m.)
Indexed 2 days, 10 hours ago (Sept. 3, 2025, 6:30 a.m.)
Issued 23 years, 11 months ago (Oct. 1, 2001)
Published 23 years, 11 months ago (Oct. 1, 2001)
Published Print 23 years, 11 months ago (Oct. 1, 2001)
Funders 0

None

@article{Panikashvili_2001, title={An endogenous cannabinoid (2-AG) is neuroprotective after brain injury}, volume={413}, ISSN={1476-4687}, url={http://dx.doi.org/10.1038/35097089}, DOI={10.1038/35097089}, number={6855}, journal={Nature}, publisher={Springer Science and Business Media LLC}, author={Panikashvili, David and Simeonidou, Constantina and Ben-Shabat, Shimon and Hanuš, Lumír and Breuer, Aviva and Mechoulam, Raphael and Shohami, Esther}, year={2001}, month=oct, pages={527–531} }